Skip to main content
. 2020 Jul 24;34(9):973–988. doi: 10.1007/s40263-020-00749-x

Fig. 1.

Fig. 1

HAD definitions and HAD patient disposition: a primary and alternative definitions of HAD used in this post hoc analysis; b CARE-MS I and II alemtuzumab-treated HAD patient disposition through year 9 defined by the primary HAD definition. CARE-MS Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, DMT disease-modifying therapy, Gd gadolinium, HAD highly active disease, MRI magnetic resonance imaging, SC IFNB-1a subcutaneous interferon-β-1a